Skip to Content

Tradjenta Approval History

FDA Approved: Yes (First approved May 2, 2011)
Brand name: Tradjenta
Generic name: linagliptin
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals Inc.
Treatment for: Diabetes, Type 2

Tradjenta (linagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Development History and FDA Approval Process for Tradjenta

DateArticle
Aug 17, 2012Approval FDA approves updated prescribing information for Tradjenta (linagliptin) tablets for add-on therapy to insulin in adults with type 2 diabetes
May  2, 2011Approval FDA Approves Tradjenta for Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide